查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012938

腦腫瘤診斷與治療市場：依治療方法、診斷方法、腫瘤類型及最終用戶分類－2026-2032年全球市場預測

Brain Tumor Diagnosis & Treatment Market by Treatment Type, Diagnosis Type, Tumor Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腦腫瘤診斷和治療市場價值將達到 19.3 億美元，到 2026 年將成長到 20.6 億美元，到 2032 年將達到 31.1 億美元，複合年成長率為 7.06%。

主要市場統計數據
基準年 2025 19.3億美元
預計年份：2026年 20.6億美元
預測年份 2032 31.1億美元
複合年成長率 (%) 7.06%

本書清晰而有力地介紹了正在重塑全球腦腫瘤診斷和治療路徑的臨床、技術和營運趨勢。

腦腫瘤的診斷和治療處於快速科學創新和複雜臨床決策的交匯點，對臨床醫生、研究人員和醫療系統領導者提出了嚴謹的應對要求。分子生物學、影像技術和治療方法的進步提高了診斷的準確性和治療選擇，但也為患者選擇、臨床工作流程、保險報銷和監管協調等領域帶來了新的複雜性。因此，相關人員必須權衡新治療方法的潛力與實際限制因素，例如設備獲取、跨學科合作以及長期治療效果的評估。

詳細檢視診斷、治療和數位技術的融合，重新定義腦腫瘤治療和臨床決策中的精準醫療之路。

腦腫瘤生態系統正經歷著一場變革性的轉變，這得益於診斷、治療和數據驅動型醫療服務等領域的進步。影像學已從解剖學描述發展到功能和分子表徵，從而能夠更早檢測治療反應和復發，並制定更精細的手術方案。同時，分子診斷技術的進步，包括基因表現分析、次世代定序和基於PCR的檢測方法，正在重新定義腫瘤的分類和預後，為治療方法的選擇提供日益關鍵的資訊。

對近期貿易政策調整和關稅趨勢如何影響腦腫瘤治療的供應鏈、籌資策略和臨床實施進行嚴謹的分析。

貿易和關稅政策的變化可能會對臨床供應鏈、科學研究採購和醫療設備的供應產生連鎖反應，進而影響腦瘤治療的實施。進口關稅和監管要求的變化可能會增加採購先進影像設備、立體定位手術器械和專用一次性用品的成本和複雜性，同時也會影響分子診斷和次世代定序流程中所用試劑的供應和價格。這些下游壓力可能會加重診斷檢查室和影像中心的運作負擔，減緩設備升級速度，並限制新診斷方法在常規臨床實踐中的應用。

透過對治療方法、診斷流程、最終用戶和腫瘤亞型進行細緻的細分，主導全面的整合，從而指導策略優先排序。

以細分觀點為出發點，明確了在每個診斷和治療路徑中應將投資和運營重點放在哪裡，從而最有效地加速以患者為中心的治療效果。根據治療類型，整體情況包括化療、免疫療法、放射線治療、手術和標靶治療。在這些類別中，化療方案包括聯合治療、亞硝基脲類藥物和Temozolomide；免疫療法包括CAR-T細胞療法、查核點抑制劑和疫苗；放射線治療包括近距離放射、體外放射治療和立體定位放射放射線手術。標靶治療方案包括Bevacizumab、mTOR抑制劑和蛋白酪氨酸激酶抑制劑，每種藥物的作用機制各不相同，因此需要量身定做的診斷策略和療效評估方法。

對影響全球醫療保健系統准入和部署的區域部署模式、基礎設施趨勢和政策背景進行詳細評估。

區域趨勢顯著影響著整個醫療保健系統中診斷創新和治療方法的引入、推廣和報銷方式。在美洲，臨床生態系統大規模綜合大學醫院到社區醫院的各種類型，為技術應用、強化專科醫療服務和多中心合作研究創造了多元化的途徑。該地區的籌資策略和報銷模式決定了先進影像、立體定位治療平台和分子檢測融入常規實踐的速度。在歐洲、中東和非洲，情況則呈現異質性，法律規範、醫療保健系統資金籌措和基礎設施的差異導致了不同的技術應用曲線。雖然功能強大的醫療中心遍布該地區，但在其他地區，獲得複雜診斷和專科手術的機會仍然有限，導致這些地區依賴轉診網路和區域卓越醫療中心。

對競爭動態、夥伴關係策略和創新重點領域進行深入分析。

腦腫瘤診斷和治療生態系統的競爭動態呈現出多元化的態勢，既有成熟的生物醫藥公司，也有新興的生物技術創新者、專業醫療設備製造商和診斷檢測實驗室。大型醫療設備和製藥公司持續利用其規模、監管經驗和分銷網路，支援影像平台、立體定位放射治療系統和已通過核准療法的廣泛臨床應用。同時，小規模的專業公司和大學衍生企業正在精準放射治療計劃、分子檢測開發和新型免疫療法等細分領域推動創新，並經常與大型機構合作，推進後期研發和商業化進程。

一系列可操作且有優先順序的策略行動，領導者可以採取這些行動來確保診斷準確性和治療創新帶來公平的臨床結果。

產業領導者必須採取前瞻性策略，將技術潛力轉化為切實的臨床價值和公平的醫療服務取得途徑。首先，投資整合診斷到治療的一體化流程，將分子譜分析、先進影像技術和多學科臨床決策無縫整合到一個統一的工作流程中。優先考慮互通性和數據標準將簡化病例審查流程，並加快治療方法的選擇。其次，透過多元化供應商關係，增強供應鏈的韌性，確保專用耗材、試劑和資本設備的供應，並制定緊急時應對計畫，以應對因政策變化或物流限制而導致的採購中斷。

透明且以臨床證據為基礎的調查方法，結合了與專家的初步訪談、系統性的文獻整合和多方面的檢驗，作為分析的基礎。

本分析採用的研究方法結合了多種定性和定量方法，以確保獲得全面且檢驗的見解。主要調查包括對臨床專業人員、實驗室管理人員、醫院採購人員和行業高管進行結構化訪談，以收集關於診斷流程、治療決策和營運限制的第一手觀點。次要調查則系統地回顧了同儕審查文獻、臨床指南更新、監管公告和公共衛生政策文件，以了解臨床實踐和技術進步的背景。

簡潔而明確的結論，將實現診斷技術進步、治療方法多樣化和改善患者預後所需的系統性要求聯繫起來。

本執行摘要全面概述了診斷創新、治療方法多樣化和系統性因素如何影響現代腦腫瘤治療。分子診斷和影像診斷的進步提高了診斷準確性，並實現了治療分層。同時，標靶治療、免疫療法和放射療法的改進也拓展了治療選擇。儘管這些進步為改善治療效果創造了機遇，但協調投資於基礎設施、人力資源發展和實證醫學研究對於確保安全有效地實施至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：腦腫瘤診斷與治療市場（依治療方法分類）

  • 化療
    • 聯合治療
    • 亞硝基脲類藥物
  • 免疫療法
    • CAR-T細胞療法
    • 查核點抑制劑
    • 疫苗
  • 放射線治療
  • 外科手術
  • 分子標靶治療

第9章：腦腫瘤診斷與治療市場（依診斷方法分類）

  • 切片檢查
    • 開放式切片檢查
    • 立體定位切片檢查
  • 診斷影像
    • 電腦斷層掃描
    • 磁振造影
    • 正子斷層掃描
    • 超音波
  • 分子診斷
    • 基因表現分析
    • 次世代定序
    • 基於PCR的檢測

第10章：依腫瘤類型分類的腦腫瘤診斷與治療市場

  • 膠質瘤
    • 星狀細胞瘤
    • 膠質母細胞瘤
    • 少突膠質細胞瘤
  • 髓母細胞瘤
  • 腦膜瘤
  • 腦下垂體瘤
    • 顱咽瘤
    • 腦下垂體腺瘤

第11章：腦腫瘤診斷與治療市場：依最終使用者分類

  • 診斷中心
  • 醫院
  • 研究機構
  • 專科診所

第12章：腦腫瘤診斷與治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：腦腫瘤診斷與治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 腦腫瘤診斷與治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國腦腫瘤診斷與治療市場。

第16章：中國腦腫瘤診斷與治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accuray Incorporated
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Canon Medical Systems Corporation
  • Eisai Co., Ltd.
  • Elekta AB
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare LLC
  • Hitachi, Ltd.
  • Koninklijke Philips NV
  • Merck & Co., Inc.
  • Novartis AG
  • Novocure Limited
  • Pfizer Inc.
  • Roche Holding AG
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Varian Medical Systems, Inc.
Product Code: MRR-437D459585B5

The Brain Tumor Diagnosis & Treatment Market was valued at USD 1.93 billion in 2025 and is projected to grow to USD 2.06 billion in 2026, with a CAGR of 7.06%, reaching USD 3.11 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.93 billion
Estimated Year [2026] USD 2.06 billion
Forecast Year [2032] USD 3.11 billion
CAGR (%) 7.06%

A clear and compelling introduction to the evolving clinical, technological, and operational landscape reshaping brain tumor diagnosis and treatment pathways globally

Brain tumor diagnosis and treatment sit at the intersection of rapid scientific innovation and complex clinical decision-making, demanding rigorous navigation by clinicians, researchers, and health system leaders. Advances in molecular biology, imaging technology, and therapeutic modalities have expanded diagnostic precision and therapeutic options, yet they have also introduced new layers of complexity around patient selection, procedural workflows, reimbursement, and regulatory alignment. Consequently, stakeholders must reconcile the promise of novel interventions with real-world constraints such as equipment access, interdisciplinary coordination, and long-term outcome measurement.

Over the past decade, the clinical narrative has shifted from one-size-fits-all strategies toward more personalized approaches that integrate molecular insights with advanced imaging and targeted therapies. As a result, frontline practice increasingly relies on integrated diagnostic pathways that combine biopsy techniques, imaging modalities, and molecular assays to produce a nuanced understanding of tumor biology. This evolution has immediate implications for clinical workflows, laboratory operations, and cross-disciplinary training, and it creates opportunities for vendors and health systems to reimagine service delivery models.

Looking ahead, the ability to translate diagnostic precision into durable therapeutic benefit will hinge on coordinated improvements across diagnostics, surgery, systemic therapies, and supportive care. Health systems that proactively invest in cross-functional capabilities-ranging from hybrid operating suites and stereotactic platforms to molecular pathology and data integration-will be better positioned to operationalize emerging evidence and improve patient outcomes. This introduction frames the subsequent sections, which explore transformational shifts, tariff-related impacts, segmentation insights, regional dynamics, competitive considerations, and actionable recommendations for leaders navigating this evolving landscape.

An in-depth examination of converging diagnostic, therapeutic, and digital innovations that are redefining precision pathways for brain tumor care and clinical decision-making

The brain tumor ecosystem is undergoing transformative shifts driven by converging advances in diagnostics, therapeutics, and data-driven care delivery. Imaging has moved beyond anatomical depiction to functional and molecular characterization, enabling earlier detection of treatment response and recurrence and permitting more nuanced surgical planning. Parallel advances in molecular diagnostics, including gene expression profiling, next generation sequencing, and PCR-based assays, have redefined tumor classification and prognostication, and they increasingly inform therapeutic selection.

On the therapeutic front, targeted agents and immunotherapies are changing the treatment algorithm. Targeted Therapy options such as bevacizumab, mTOR inhibitors, and tyrosine kinase inhibitors provide mechanistic precision for select tumor subtypes, while immunotherapy approaches including CAR T-cell therapy, checkpoint inhibitors, and cancer vaccines are extending lines of inquiry into durable anti-tumor immunity. Radiotherapy innovation, spanning external beam modalities, stereotactic radiosurgery, and brachytherapy, is enhancing focal control with reduced collateral toxicity. Surgical technology has likewise advanced, with image-guided resection and minimally invasive stereotactic approaches improving the balance between maximal resection and functional preservation.

Digital transformation is amplifying these clinical innovations. Artificial intelligence and machine learning augment imaging interpretation, automate segmentation, and support prognostic modeling, thereby shortening diagnostic timelines and enabling more personalized surveillance strategies. Interoperability of clinical and genomic data supports multidisciplinary tumor boards and accelerates translational research. Taken together, these shifts are creating a landscape in which precision diagnostics and multimodal treatment converge to offer individualized pathways, while simultaneously raising pressing questions about equitable access, reimbursement policy, and the workforce competencies required to realize these benefits at scale.

A rigorous analysis of how recent trade policy adjustments and tariff dynamics are influencing supply chains, procurement strategies, and clinical adoption in brain tumor care

Policy shifts in trade and tariffs can produce ripple effects across clinical supply chains, research procurement, and device availability that materially influence the delivery of brain tumor care. Changes to import duties and regulatory requirements raise the cost and complexity of sourcing advanced imaging hardware, stereotactic equipment, and specialized disposables, while also affecting the availability and pricing of reagents used in molecular diagnostics and next generation sequencing workflows. These downstream pressures can increase operational burden for diagnostic laboratories and imaging centers, delay capital upgrades, and constrain the pace at which new diagnostic modalities are adopted in routine clinical practice.

Beyond direct procurement impacts, tariff-driven shifts can reshape partnerships between domestic and international suppliers, prompting manufacturers to reevaluate production footprints and supply chain redundancy. In response, providers and research institutions may prioritize strategic procurement, develop longer inventory lead times, and diversify vendor relationships to mitigate supply risk. Importantly, tariff-induced cost pressures can also influence pricing negotiations with payers, slow adoption of capital-intensive therapeutic platforms, and prompt system-level decisions around where specialized services are centralized to achieve economies of scale.

For research networks and clinical trials, changes to cross-border movement of biological materials, instrumentation, and diagnostic kits can introduce logistical hurdles that affect trial initiation and sample processing timelines. Consequently, research sponsors and clinical investigators must anticipate and incorporate trade-related contingencies into study design and budgeting. In the aggregate, tariff dynamics act as a non-clinical determinant of access and innovation, underscoring the need for proactive supply chain strategies, policy engagement, and adaptive procurement models to preserve the momentum of improvements in brain tumor diagnosis and treatment.

A comprehensive segmentation-driven synthesis connecting treatment modalities, diagnostic workflows, end users, and tumor subtype nuances to guide strategic prioritization

A segmentation-aware perspective illuminates where investment and operational focus will most effectively accelerate patient-centered outcomes across diagnostic and therapeutic pathways. Based on Treatment Type, the clinical landscape encompasses Chemotherapy, Immunotherapy, Radiotherapy, Surgery, and Targeted Therapy; within these categories, Chemotherapy pathways include combination therapies, nitrosoureas, and temozolomide, while Immunotherapy encompasses CAR T-cell therapy, checkpoint inhibitors, and vaccines, and Radiotherapy comprises brachytherapy, external beam radiotherapy, and stereotactic radiosurgery. Targeted Therapy options span bevacizumab, mTOR inhibitors, and tyrosine kinase inhibitors, each offering distinct mechanisms that require aligned diagnostic strategies and outcome measurement.

Diagnostic segmentation further clarifies clinical workflows and laboratory needs. Based on Diagnosis Type, the diagnostic continuum includes biopsy, imaging, and molecular diagnostics; biopsy procedures range from open biopsy to stereotactic biopsy, imaging modalities include computed tomography, magnetic resonance imaging, positron emission tomography, and ultrasound, and molecular diagnostics incorporate gene expression profiling, next generation sequencing, and PCR-based assays to provide molecular context for therapeutic choice and prognostication. These diagnostic modalities interact closely with treatment selection and surveillance paradigms and inform the design of multidisciplinary care pathways.

End user segmentation highlights where services are delivered and where capacity constraints may emerge. Based on End User, care is provided across diagnostic centers, hospitals, research institutes, and specialty clinics, each with distinct infrastructure, staffing models, and reimbursement interfaces. Tumor type segmentation brings clinical heterogeneity into focus. Based on Tumor Type, the principal categories include glioma, medulloblastoma, meningioma, and pituitary tumor; glioma includes astrocytoma, glioblastoma, and oligodendroglioma, while pituitary tumor distinctions include craniopharyngioma and pituitary adenoma. Aligning therapeutic modalities and diagnostic intensity with tumor subtype is essential for optimizing outcomes and resource allocation, and it emphasizes the need for integrated care pathways that span diagnosis through long-term surveillance.

A nuanced assessment of regional adoption patterns, infrastructure dynamics, and policy contexts shaping access and implementation across global health systems

Regional dynamics exert a profound influence on how diagnostic innovations and therapeutic modalities are adopted, scaled, and reimbursed across health systems. In the Americas, clinical ecosystems vary from large integrated academic medical centers to community hospitals, producing diverse pathways for technology adoption, centralized specialty services, and multisite research collaboration; procurement strategies and reimbursement models in this region shape the pace at which advanced imaging, stereotactic platforms, and molecular testing are integrated into standard practice. Europe, Middle East & Africa presents a heterogeneous picture in which regulatory frameworks, health system financing, and infrastructure disparities create differentiated adoption curves; pockets of high-capacity centers coexist with regions where access to complex diagnostics and specialty surgery remains limited, prompting a reliance on referral networks and regional centers of excellence.

Asia-Pacific demonstrates rapid capacity expansion in both clinical infrastructure and domestic manufacturing of diagnostic reagents and medical devices, accompanied by growing participation in international clinical research and cross-border collaboration. The convergence of public investment in tertiary healthcare and increased private sector involvement in many Asia-Pacific markets accelerates the diffusion of technology, while also creating varied payer landscapes that affect affordability and access. Across all regions, interoperability of clinical and genomic data, workforce training, and telemedicine-enhanced networks act as enablers for expanding access to specialist expertise. Understanding regional nuances is critical for tailoring implementation strategies, aligning commercial engagement, and structuring collaborative research that accounts for local regulatory, economic, and clinical realities.

An incisive review of competitive dynamics, partnership strategies, and innovation focus areas that determine which companies will drive clinical adoption and service evolution

Competitive dynamics in the brain tumor diagnosis and treatment ecosystem reflect a blend of established biomedical firms, emerging biotechnology innovators, specialized device manufacturers, and diagnostic laboratories. Large medical device and pharmaceutical companies continue to leverage scale, regulatory experience, and distribution networks to support wide clinical deployment of imaging platforms, stereotactic systems, and approved therapeutics. At the same time, smaller specialized firms and academic spin-outs drive innovation in niche areas such as precision radiotherapy planning, molecular assay development, and novel immunotherapeutic constructs, often partnering with larger organizations to progress late-stage development and commercialization.

Strategic collaborations between diagnostics providers and therapeutic developers are becoming increasingly important as treatment decisions rely on integrated biomarker and imaging information. Partnerships that bridge laboratory-developed tests, next generation sequencing, and clinical trial networks facilitate patient stratification and accelerate translational pipelines. Intellectual property strategy, regulatory pathway navigation, and real-world evidence generation are key differentiators for companies that seek durable clinical adoption. Moreover, contract research organizations, specialty service providers, and regional distributors play a pivotal role in enabling clinical trial logistics and localized deployment of complex technologies.

For stakeholders evaluating competitor behavior, attention should focus on areas of active investment such as molecular diagnostics platforms, AI-enabled imaging solutions, stereotactic radiosurgery systems, and cell therapy manufacturing capacity. Companies that combine robust clinical evidence generation with clear reimbursement strategies and scalable service models are best positioned to transform innovations into widespread clinical utility. Ultimately, success hinges on aligning commercial strategy with clinical workflows, payer requirements, and the operational realities of centers delivering neuro-oncology care.

A set of practical and prioritized strategic actions that leaders can implement to ensure diagnostic precision and therapeutic innovation translate into equitable clinical impact

Industry leaders must adopt proactive strategies to translate technological potential into consistent clinical value and equitable access. First, invest in integrated diagnostic-to-therapy pathways that bring molecular profiling, advanced imaging, and multidisciplinary clinical decision-making into seamless workflows; prioritizing interoperability and data standards will streamline case review and accelerate therapy selection. Second, strengthen supply chain resilience by diversifying vendor relationships for specialized consumables, reagents, and capital equipment, and by developing contingency plans that address procurement disruptions caused by policy shifts or logistical constraints.

Third, forge collaborative partnerships across academic centers, community providers, and industry to broaden patient access to specialized diagnostics and novel therapies, while also enabling larger, more representative clinical studies. Fourth, align evidence generation with payer expectations by designing clinical and real-world studies that demonstrate comparative effectiveness, patient-centered outcomes, and cost implications relevant to reimbursement decisions. Fifth, invest in workforce development and cross-disciplinary training to ensure clinicians, pathologists, radiologists, and laboratory staff can operationalize complex diagnostic algorithms and deliver multimodal treatments safely and effectively.

Finally, adopt a patient-centric commercialization strategy that considers equity and affordability, including tiered delivery models, telemedicine-enabled networks, and regional centers of excellence that concentrate high-complexity care. By implementing these actions, leaders can convert scientific advances into scalable clinical benefits while managing operational risk and strengthening stakeholder alignment across health systems.

A transparent and clinically grounded methodology combining primary expert interviews, systematic literature synthesis, and multi-source validation to underpin the analysis

The research approach underpinning this analysis combined multifaceted qualitative and quantitative methods to ensure comprehensive and validated findings. Primary research comprised structured interviews with clinical specialists, laboratory directors, hospital procurement leaders, and industry executives to capture firsthand perspectives on diagnostic workflows, therapeutic decision-making, and operational constraints. Secondary research involved systematic review of peer-reviewed literature, clinical guideline updates, regulatory communications, and public health policy documents to contextualize clinical practice and technology trajectories.

Data synthesis employed triangulation techniques to reconcile insights from primary interviews with published evidence and industry disclosures. Validation rounds with subject matter experts ensured that interpretations of technological capability, regulatory pathways, and operational feasibility reflected current practice patterns. Ethical considerations guided the research, including protection of confidential information shared during interviews and de-identification of sensitive operational details. Limitations of the methodology included variability in regional data granularity and evolving evidence bases for emerging therapies; where appropriate, findings emphasize directional insights and implementation considerations rather than definitive long-term projections.

Overall, the methodology prioritized transparency, cross-validation, and clinical relevance to produce an analysis that supports operational decision-making, strategic planning, and further research collaboration within the brain tumor diagnosis and treatment domain.

A concise and decisive conclusion tying together diagnostic advances, therapeutic diversification, and systemic imperatives required to realize improved patient outcomes

This executive summary synthesizes how diagnostic innovation, therapeutic diversification, and systemic factors jointly shape contemporary brain tumor care. Advances in molecular diagnostics and imaging have enhanced diagnostic precision and informed treatment stratification, while targeted therapies, immunotherapies, and radiotherapy refinements are expanding therapeutic options. These developments create opportunities for improved outcomes but also necessitate coordinated investments in infrastructure, workforce training, and evidence generation to ensure safe and effective adoption.

External forces such as trade policy dynamics and regional infrastructure disparities influence the speed and equity of implementation, affecting procurement, research logistics, and access to advanced care. Competitive dynamics reveal that successful entities will be those that integrate diagnostic and therapeutic value propositions, demonstrate clinical and economic value, and build scalable service delivery models. Actionable recommendations center on creating integrated pathways, strengthening supply chain resilience, fostering collaborative networks, aligning evidence generation with payer needs, and committing to workforce and access initiatives.

In closing, realizing the promise of improved brain tumor care will require coordinated action across clinicians, health systems, industry, and policymakers. Stakeholders who proactively align technological capability with operational readiness and equitable delivery models will be best positioned to convert innovation into meaningful patient benefit and sustainable system impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Tumor Diagnosis & Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Combination Therapies
    • 8.1.2. Nitrosoureas
  • 8.2. Immunotherapy
    • 8.2.1. Car T-Cell Therapy
    • 8.2.2. Checkpoint Inhibitors
    • 8.2.3. Vaccines
  • 8.3. Radiotherapy
  • 8.4. Surgery
  • 8.5. Targeted Therapy

9. Brain Tumor Diagnosis & Treatment Market, by Diagnosis Type

  • 9.1. Biopsy
    • 9.1.1. Open Biopsy
    • 9.1.2. Stereotactic Biopsy
  • 9.2. Imaging
    • 9.2.1. Computed Tomography
    • 9.2.2. Magnetic Resonance Imaging
    • 9.2.3. Positron Emission Tomography
    • 9.2.4. Ultrasound
  • 9.3. Molecular Diagnostics
    • 9.3.1. Gene Expression Profiling
    • 9.3.2. Next Generation Sequencing
    • 9.3.3. Pcr-Based Assays

10. Brain Tumor Diagnosis & Treatment Market, by Tumor Type

  • 10.1. Glioma
    • 10.1.1. Astrocytoma
    • 10.1.2. Glioblastoma
    • 10.1.3. Oligodendroglioma
  • 10.2. Medulloblastoma
  • 10.3. Meningioma
  • 10.4. Pituitary Tumor
    • 10.4.1. Craniopharyngioma
    • 10.4.2. Pituitary Adenoma

11. Brain Tumor Diagnosis & Treatment Market, by End User

  • 11.1. Diagnostic Centers
  • 11.2. Hospitals
  • 11.3. Research Institutes
  • 11.4. Specialty Clinics

12. Brain Tumor Diagnosis & Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Brain Tumor Diagnosis & Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Brain Tumor Diagnosis & Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Brain Tumor Diagnosis & Treatment Market

16. China Brain Tumor Diagnosis & Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Accuray Incorporated
  • 17.6. AstraZeneca PLC
  • 17.7. Bayer AG
  • 17.8. Bristol-Myers Squibb Company
  • 17.9. Canon Medical Systems Corporation
  • 17.10. Eisai Co., Ltd.
  • 17.11. Elekta AB
  • 17.12. F. Hoffmann-La Roche Ltd.
  • 17.13. GE Healthcare LLC
  • 17.14. Hitachi, Ltd.
  • 17.15. Koninklijke Philips N.V.
  • 17.16. Merck & Co., Inc.
  • 17.17. Novartis AG
  • 17.18. Novocure Limited
  • 17.19. Pfizer Inc.
  • 17.20. Roche Holding AG
  • 17.21. Siemens Healthineers AG
  • 17.22. Thermo Fisher Scientific Inc.
  • 17.23. Varian Medical Systems, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY ADENOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY ADENOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY ADENOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 234. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 235. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 236. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 238. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 239. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 270. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 271. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 272. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 274. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 275. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 283. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 284. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 286. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 287. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES BRAIN TUMOR DIA